New US dedicated trainer account

RNS Number : 0528J

Deltex Medical Group PLC

01 April 2015

 



Deltex Medical Group plc

("Deltex Medical", "the Company" or "the Group")

New US dedicated trainer account

1 April 2015 - Deltex Medical Group plc (LSE-AIM: DEMG), the global leader in oesophageal Doppler monitoring ("ODM"), today announces that it has established its eighth dedicated trainer account in the USA.

The new account is a major Level 1 Trauma Centre and follows a successful clinical evaluation of CardioQ-ODM+ between August and October 2014. Management expect monthly usage to commence at 50 probes and the necessary approvals are in place for expansion of usage across all types of major surgery and critical care.

This is the first dedicated trainer account to be established in the Mid-Atlantic region of the USA in a sales territory newly created in the final quarter of 2014.

Ewan Phillips, Deltex Medical's Chief Executive, commented:

"This is the second dedicated trainer account established this year and the eighth in total. This creates further substantial progress towards delivering our strategy of building a profitable network of influential major hospitals adopting our products as standards of care. This network will form a strong platform for future national roll-out of ODM in the key US market."

For further information, please contact:-

Deltex Medical Group plc	01243 774 837 [e-mail]
Nigel Keen, Chairman
Ewan Phillips, Chief Executive
Paul Mitchell, Finance Director
Nominated Adviser & Broker
Arden Partners plc	020 7614 5900
Chris Hardie
Joint Broker Zeus Capital Limited Dominic Wilson John Goold	020 7533 7727
Financial Public Relations
Newgate	020 7653 9850
Tim Thompson Ed Treadwell Robyn McConnachie

  

Notes for Editors

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's ODM is the only technology to measure blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.

During 2013, the Company launched the CardioQ-ODM+ monitor that offers clinicians both of the two best-established technologies, Deltex Medical's ODM technology as well as Pulse Pressure Waveform Analysis ('PPWA') in one monitor. This allows clinicians to have unique real time insights into each of flow, pressure and resistance, the three pillars of haemodynamics.

Company goal

ODM is increasingly recognised as a standard of care for patients undergoing major surgery and in critical care. The broader clinical area of haemodynamic management of which ODM is a core constituent is also now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world.

The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.

There are over 3,200 monitors installed in hospitals around the world and over 600,000 patients have been treated to date using Deltex Medical's single patient disposable probes.

 

END

 

 

NRAJBMITMBAJBRA